Future: Dedicated NASH Phase 3 Trial - NOT YET STARTED Status: Expected 2027-2030 (after obesity/diabetes approval) What This Would Include: Liver biopsy as PRIMARY endpoint NASH resolution as primary outcome Fibrosis improvement measurement Required for FDA approval specifically for NASH indication Why Wait
AMPK agonists inhibit ferroptosis by activating AMPK, which subsequently upregulates GPX4 expression and downregulates lipocalin-2 expression in vivo (63)
Conclusion Taking topiramate with Ozempic is a clinical strategy that may be effective for some individuals, particularly those who have hit a weight loss plateau or struggle with specific neurological hunger triggers
R., Radwan, P., Radwan, M., Barcz, E., Poski, R., Motak-Pochrzst, H., Banasik, M., Sobczyski, M., & Kunierczyk, P
Detailed statistical methodology is described in the Supplemental Methods
Mild and temporary side effects may include localized injection site irritation, transient water retention, or changes in appetite